David H. Mack - Apr 27, 2022 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role: President and CEO, Director
Signature: /s/ David H. Mack
Stock symbol: PMVP
Transactions as of: Apr 27, 2022
Transactions value $: $17,490
Form type: 4
Date filed: 4/29/2022, 09:15 PM
Previous filing: Mar 9, 2022
Next filing: May 15, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PMVP	Common Stock	Options Exercise	$17.5K	+33K	+70.26%	$0.53^*	80K	Apr 27, 2022	Direct
holding	PMVP	Common Stock						148K	Apr 27, 2022	See footnote	F1
holding	PMVP	Common Stock						80K	Apr 27, 2022	See footnote	F2
holding	PMVP	Common Stock						57K	Apr 27, 2022	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PMVP	Employee Stock Option (right to buy)	Options Exercise	$0	-33K	-7.74%	$0.00	393K	Apr 27, 2022	Common Stock	33K	$0.53	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are held of record by The Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F2	The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F3	The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F4	The shares subject to the option are fully vested and immediately exercisable.
F5	Due to an administrative error, the Form 4 filed on May 24, 2021 overstated the number of derivative securities beneficially owned following the reported transaction by 6,207 shares and has been updated in this Form 4 to correct the error.